EAACI Congress 2025
BackOAS15 - Outcomes in chronic rhinosinusitis and type 2 inflammation
Sunday 15 Jun, 14:00 PM -
15:30 PM Glasgow, United Kingdom
Carron 1
Oral Abstract Sessions
14:00
Characterization of chronic rhinosinusitis patients based on markers of type 2 inflammation: Findings from the European CRS Outcome Registry (CHRINOSOR)
14:12
Distribution of Baseline Type 2 Inflammation Characteristics in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Biologic Clinical Trials: A Comparative Assessment
14:24
Real-Life Effectiveness of Monoclonal Antibody Therapy in Severe Uncontrolled Chronic Rhinosinusitis with Nasal Polyps: A Prospective Study
14:36
Dupilumab Treatment is Associated with Clinical Improvement and a Shift towards a health-associated Nasal Passage Microbiota in Diffuse Type 2 Chronic Rhinosinusitis
14:48
Association between olfactory function, nasal polyp score, nasal obstruction and quality of life in CRSwNP patients treated with dupilumab
15:00
Construction of prediction model for olfactory dysfunction improvement in patient with chronic rhinosinusitis after endoscopic sinus surgery
15:12
Emerging Biologic Use May Reduce the Need for Corticosteroid Treatment and Surgery for Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in France, Germany, Italy, Spain and the UK
